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mary sclerosing cholangitis, hampering patient care and the 18 proteins in the validation panel. Interleukin (IL)-8, matrix met-
development of therapy. We aimed to identify novel protein
biomarkers of disease severity and prognosis in primary scleros-
ing cholangitis (PSC).
Methods: Using a bead-based array targeting 63 proteins, we
profiled a derivation panel of Norwegian endoscopic retrograde
cholangiography bile samples (55 PSC, 20 disease controls) and a
Finnish validation panel (34 PSC, 10 disease controls). Selected
identified proteins were measured in serum from two Norwegian
PSC cohorts (n = 167 [1992–2006] and n = 138 [2008–2012]),
inflammatory bowel disease (n = 96) andhealthy controls (n = 100).
Results: In the bile derivation panel, the levels of 14 proteins were
different between PSC patients and controls (p <0.05); all were
confirmed in the validation panel. Twenty-four proteins in the bile
derivation panel were significantly (p <0.05) different between
PSC patients with mild compared to severe cholangiographicJournal of Hepatology 20
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y These authors jointly supervised the work.allopeptidase (MMP)9/lipocalin (LCN)2-complex, S100A8/9,
S100A12 and tryptophan hydroxylase (TPH)2 in the bile were
associated with both a PSC diagnosis and grade of cholangio-
graphic changes. Stratifying PSC patients according to tertiles of
serum IL-8, but not MMP9/LCN2 and S100A12, provided excellent
discrimination for transplant-free survival both in the serum
derivation and validation cohort. Furthermore, IL-8 was associ-
ated with transplant-free survival in multivariable analyses in
both serum panels independently of age and disease duration,
indicating an independent influence on PSC progression. How-
ever, the Enhanced Liver Fibrosis (ELF) test and Mayo risk score
proved to be stronger predictors of transplant-free survival.
Conclusions: Based on assaying of biliary proteins, we have iden-
tified novel biliary and serum biomarkers as indicators of severity
and prognosis in PSC.
Lay summary: Prognostic biomarkers are lacking in primary scle-
rosing cholangitis, hampering patient care and the development
of therapy. We have identified inflammatory proteins including
calprotectin and IL-8 as important indicators of disease severity
and prognosis in bile and serum from patients with primary scle-
rosing cholangitis.
 2017 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.17 vol. 66 j 1214–1222
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Introduction
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver
disease characterized by progressing inflammation and fibrosis of
the intra- and extrahepatic bile ducts, leading to cirrhosis in the
majority of patients. PSC is frequently associated with inflamma-
tory bowel disease (IBD) and other immunological diseases. To
date, liver transplantation is the only curative treatment in PSC,
as there is no medical therapy of proven benefit to halt disease
progression. The disease course is highly variable between PSC
patients, with transplant-free survival ranging from 12–21 years
in different cohorts [1,2].
Predictors of outcome in terms of liver transplantation or
death have been proposed, mainly based on biochemical vari-
ables (e.g. bilirubin or alkaline phosphatase) or clinical signs
(e.g. variceal bleeding or ascites) [3], but currently there are no
validated prognostic tools to reliably estimate the prognosis in
the individual patient [4,5]. Furthermore, the lack of validated
biomarkers reflecting relevant disease inflammatory activity is
a major hurdle for clinical trials struggling to demonstrate effect
of new therapeutic options. A position paper was recently pub-
lished by the International PSC Study Group aiming to define sur-
rogate endpoints for clinical trials based on a consensus process
[6]. Biomarkers reflecting liver fibrosis including the serum-
based Enhanced Liver Fibrosis (ELF; Siemens Medical Solutions
Diagnostics Inc., Tarrytown, NY, USA) test have been reported
to predict prognosis in PSC [7]. Although promising biomarkers,
a critical question is whether the proposed markers reflect dis-
ease activity or disease stage.
In this study, we aimed to explore whether inflammatory
biomarkers or biomarkers of fibrosis other than ELF represent
biomarkers of disease activity or disease stage in large-duct
PSC. As bile is in immediate contact with the primary target of
the disease, i.e. the cholangiocytes (of the bile ducts), we hypoth-
esized that the biliary protein pool would be more likely than
serum to accurately reflect disease activity. In order to investigate
this we performed an exploratory analysis of a large number of
putative biomarker proteins in bile, using a custom multiplex
antibody array platform and applying a two-step analysis with
validation of significant results in an independent panel. Sec-
ondly, we investigated the prognostic potential of key proteins
identified in bile, in sera from two independent cohorts by a sim-
ilar two-step derivation-validation analysis.Materials and methods
Patient population and data collection
PSC was diagnosed based on typical cholangiographic findings according to
acknowledged criteria after the exclusion of secondary causes of sclerosing
cholangitis, and excluding small duct PSC [8,9]. The first pathological cholangio-
graphy defined the time of PSC diagnosis. For the PSC patients, we queried patient
records and research databases for information on clinical and laboratory data,
including fever, cholangitis, jaundice, ascites, encephalopathy, esophageal varices,
variceal bleeding, IBD status, colorectal or hepatobiliary malignancy, and medica-
tion at the time of bile or serum extraction. IBD diagnosis was based on colono-
scopy and histology findings. Diagnoses of ulcerative colitis (UC) and Crohn’s
disease were established by accepted criteria. We retrieved updated information
on liver transplantation dates and indications (Table S1) by December 31st 2012
from the Nordic Liver Transplant Registry and data on all-cause death by the same
date from the Norwegian Death Registry.Journal of Hepatology 2017We included two panels of bile samples; an exploratory derivation panel (bile
panel-1), and an independent validation panel (bile panel-2) (Fig. S1A). We
selected bile samples from PSC patients based on clinical and laboratory data in
order to constitute groups of varying disease activity, applying the original Ams-
terdam score [10] to categorize the PSC patients into groups of ‘‘mild” or ‘‘ad-
vanced” disease (Amsterdam scores 0–2 or 3, respectively) based on revision
of endoscopic retrograde cholangiography (ERC) images. Bile panel-1 consisted
of bile samples extracted at ERC from 55 large-duct PSC patients (16 mild, 37
advanced) and 20 disease controls (details in Fig. S1) retrieved from the NoPSC
Biobank, Oslo, Norway (Table 1). Bile panel-2 included bile samples extracted
at ERC from a Finnish cohort of 34 PSC patients (12 mild, 22 advanced) and 10
controls (Table 1).
For the serum analyses, we adopted a two-step study design including two
PSC panels recruited during two different, well-defined time periods (Fig. S1B).
The panels were not overlapping. Statistically significant results obtained in
serum panel-1 were tested in serum panel-2. Serum panel-1 included serum sam-
ples from 167 large-duct PSC patients (median follow-up time of 4 years [range:
0–20.1] from time of serum sampling) collected during 1992–2006. Serum panel-
2 included 138 independent PSC patients (median follow-up time of 2.2 years
[range: 0.0–4.3] from serum sampling) were collected during 2008–2012 from
the NoPSC Biobank. Control serum panels of 100 healthy controls and 96 UC cases
from a population based Norwegian cohort were retrieved for comparison [11].
The characteristics of the study populations are shown in Table 2.
Standard biochemical analyses were retrieved from clinical routine labora-
tory databases including C-reactive protein, white blood count, platelets, crea-
tinine, total bilirubin, albumin, international normalized ratio (INR), aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase
(ALP) and gamma-glutamyltransferase (GGT). Mayo risk scores were calculated
using the algorithm for the revised Mayo risk score [12].
Ethical approval
The protocol was in accordance with Declaration of Helsinki and approved by the
regional committee for research ethics in South Eastern Norway (reference num-
ber 2011/2572). All study participants provided written, informed consent.
Bile sample preparation
The samples were thawed and 100 ll of bile was added to 150 ll PBS containing
0.1% Tween 20 and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Missouri,
USA), then centrifuged at 4 C for 10 min at 14,000 rpm. CleanAsciteTM (100 ll, Bio-
tech Support Group, NJ, USA) and Protein G Sepharose (50 ll; Sigma-Aldrich) were
used for removal of lipids and immunoglobulins, respectively. Proteins were
labelled with amine-reactive biotin (NHS-PEO4-Biotin 1 mg/mL, Thermo Fischer
Scientific, IL, USA) for 45 min on ice and separated on a Superdex 200 10/300 GL
SEC column coupled to an Äkta Purifier (GE Lifesciences). The mobile phase was
PBS containing 0.05% Tween 20 at a flow rate of 0.5 ml/min. After a retention vol-
ume of 8 ml, 24 fractions of 0.5 ml each were collected. The fractions were ali-
quoted and stored at 70 C until analysis. The samples and fractions were kept
cold at all times during the preparation procedure to limit proteolysis.
Antibody array analysis
The production of the bead-based antibody array has been described in detail
elsewhere [13]. The antibodies used are commercially available and have been
evaluated thoroughly in-house with regard to specificity prior to the current
study [14]. A comprehensive list of the antibodies used is provided in Table S2.
Antibody-coupled beads were mixed, aliquoted and stored at 70 C. Mixtures
of beads with up to 1728 different color codes were added to SEC fractions con-
taining biotinylated bile proteins. After overnight incubation, the beads were
washed three times with PBS containing 1% Tween 20 (PBT). Streptavidin-
conjugated phycoerythrin was added to label captured biotinylated proteins
(SA-PE, Jackson Immunoresearch). The beads were washed in PBT and analysed
with an LSRII flow cytometer (BD Biosciences, San Jose, California, USA) as
described previously [13]. Flow cytometry files were analysed with a customized
software capable of automatically reading the fluorescent bar codes of micro-
sphere subsets and exporting the median SA-PE fluorescence in text format
[15]. The data output is reactivity profiles for all antibodies in the array where
molecular size is on the x-axis and fluorescence intensity on the y-axis. Specific
target capture is visualized as peaks in the reactivity profile. In order to obtain
quantitative data we calculated the peak areas using scripts in Microsoft Excel.vol. 66 j 1214–1222 1215
Table 1. Baseline characteristics of PSC patients and controls at the time of bile extraction.
Bile panel-1 Bile panel-2
PSC* Controls⁄ PSC Controls
N 55 20 34 10
Males, n (%) 45 (81.8) 10 (50) 23 (67.6) NI
Age, median (range) 36.2 (16–70) 45.5 (18–75) 35.4 (19–52) NI
PSC duration, yr, median (range) 0.2 (0–24) n.a. 0.0 (0–21) n.a.
PSC-AIH, n (%) 9 (16.4) n.a. 1 (2.3) n.a.
Amsterdam score, median (range) 3.0 (2–4) n.a. 3.0 (2–4) n.a.
Amsterdam score 3, n (%) 33 (42.9) n.a. 19 (57.6) n.a.
IBD, n (%) (final)§ 38 (79.2) NI 25 (78.1) NI
Ulcerative colitis, n (% of IBD) 27 (71.1) NI 21 (84.0) NI
Crohn’s disease, n (% of IBD) 6 (15.8) NI 2 (8.0) NI
Indeterminate colitis, n (% of IBD) 5 (13.2) NI 2 (8.0) NI
Mayo score 0.04 (1.96 to 3.28) n.a. 0.70 (1.6 to 2.21) n.a.
Mayo risk low/intermed./high, n (%) 27/17/8 (51.9/32.7/15.4) n.a. 24/7/1 n.a.
Treatment
UDCA, n (%) 21 (38.2) 3 (15) 20 (58.8) NI
5-ASA, n (%) 18 (32.7) 1 (5) 16 (47.1) NI
Prednisolone, n (%) 15 (27.3) 2 (10) 1 (2.9) NI
Laboratory data
CRP, median (range) 2.9 (0.6–36.9) 3.0 (0.6–38.9) 2.9 (2.9–17.0)
White blood count, median (range) 6.1 (2.1–18.6) 5.9 (3.3–12.3) 5.4 (3.0–10.0)
Platelets, 109/L, median (range) 270 (70–903) 260 (107–412) 257 (64–475)
Total bilirubin, mmol/L, median (range) 18.3 (4.8–532) 14.5 (6.0–248.4) 12.0 (4.0–87.0)
Albumin, g/L, median (range) 41.0 (24.5–49.8) 41.9 (31.2–49.0) 40.1 (24.8–49.6)
INR, median (range) 1.1 (0.89–2.04) 1.0 (0.9–1.27) 1.0 (0.9–1.7)
Creatinine, mmol/L, median (range) 64.0 (36.0–89.0) 62.0 (45.0–85.0) 68.0 (44.0–101.0)
AST, U/L, median (range) 67.0 (16.0–1219.0) 39.0 (16.0–412.0) 41.0 (21.0–342.0)
ALT, U/L, median (range) 94.0 (14.0–885.0) 51.5 (14.0–613.0) 56.0 (12.0–579.0)
ALP, U/L, median (range) 226.5 (52.0–788.0) 130.5 (36.0–633.0) 125.0 (47.0–607.0)
GGT, U/L, median (range) 258.5 (23.0–1620.0) 147.0 (12.0–2334.0) 118.0 (10.0–908.0)
Patients with large-duct PSC and bile extracted at ERC available were selected retrospectively in two independent cohorts (bile panel-1 and -2) and compared to disease
controls with various liver diseases other than PSC.
* Missing data, bile panel-1; PSC: Two patients had missing data for all laboratory data and Mayo score; thus, n = 52 for Mayo score and all laboratory data except INR
(n = 46); n = 53 for Amsterdam score. Controls: Two controls have missing data for all lab results; thus, n = 18 for laboratory data except for INR (n = 16) and AST and Mayo
score (n = 17).
§ IBD status: Percentages relate to patients with a diagnosis verified by colonoscopy; e.g. in bile panel-1, screening colonoscopy had been performed in 10 out of 16 patients
categorized as not having IBD, thus IBD was present in 38/48 = 79.2%. PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; IBD, inflammatory bowel disease; n.
a., not applicable; CRP, C-reactive protein; INR, international normalized ratio; NS, not significant (p 0.05); NI, not investigated; IBD, inflammatory bowel disease; UDCA,
ursodeoxycholic acid; 5-ASA, 5-aminosalicylic acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-
glutamyltransferase.
Research ArticleELISA
Commercial kits from RnD Systems (Minneapolis, MN, US) were used to analyse
serum levels of interleukin (IL)-8, S100A12 and the matrix metallopeptidase
(MMP)9-lipocalin (LCN)2 complex in frozen serum samples from all 305 PSC
patients, the 100 healthy controls and the 96 UC patients. Serum levels of trypto-
phan hydroxylase 2 (TPH2) were analysed using a commercial kit from Cusabio
(Baltimore, MD, US; cat number CSB-EL02410HU) in frozen serum samples from
137 patients in serum panel-2. Inter- and intra-assay coefficients of variation
were <10% for the biochemical analyses for all of the associated markers. Plasma
levels of calprotectin (S100A8/A9 complex) were analysed in serum panel-2
(n = 138) using a commercial kit (Calprolab, Calpro, Lysaker, Norway).
Statistical analyses
Statistical analyses were performed using SPSS (version 21, SPSS Inc., Chicago, IL,
USA), MedCalc (MedCalc Software, Ostend, Belgium) and R (R Foundation for Sta-
tistical Computing, Vienna, Austria). p values of <0.05 were considered significant.
Continuous variables were tested for normal distribution and the Student’s t test
or the Mann-Whitney U test was applied as appropriate. Data are presented as
median (range). Spearman’s rho was used to test for correlations between puta-
tive biomarkers and prognostic scores.1216 Journal of Hepatology 2017Predictive values of putative biomarkers were evaluated by receiver operat-
ing characteristic (ROC) curves and are presented as area under the curves (AUCs)
with 95% confidence intervals (CI). Optimal cut-off values were determined by
ROC analyses according to the Youden’s index and we calculated sensitivities
and specificities of each protein to differentiate between PSC patients and con-
trols. Primary endpoint was time to death or liver transplantation. We explored
the associations between tertiles of IL-8, S100A12, the MMP-LCN2 complex and
TPH2 and clinical outcome by the Kaplan-Meier method and tested statistical sig-
nificance by the log-rank test.
We assessed the associations between clinical, laboratory and radiological
features at the time of first diagnosis and clinical outcome by univariate Cox pro-
portional hazards regression analyses. Factors found to be of prognostic signifi-
cance by univariate analysis were entered into a multivariable model to
identify factors independently related to prognosis. From these, a prognostic
model was constructed. IL-8 and ELF and Mayo score were assessed in different
Cox models owing to collinearity (r >0.5). Lasso analysis [16] using the R penal-
ized package was performed to find subsets of biomarkers best discriminating
between PSC vs. controls and severe vs. mild PSC, respectively. To avoid overfit-
ting due to multiple explanatory variables (the 63 biomarkers), we first trained
the lasso models on bile panel-1, using cross-validation to find the optimal penal-
ization parameter. The coefficient estimates of these trained models were used to
evaluate model performance (AUC) using bile panel-2 as an independent test data
set. In all tests, p values of <0.05 were considered statistically significant.vol. 66 j 1214–1222
Table 2. Baseline characteristics of the PSC patients in serum panel-1 and -2.
Derivation panel Validation panel
Tx-free survivorsA Tx/deathB p value Tx-free survivorsC Tx/deathD p value
N 52 115 91 47
Males, n (%) 38 (73.1) 86 (74.8) n.s. 73 (80.2) 34 (72.3) n.s.
Age, mean (95% CI) 35.1 (31.4, 38.8) 42.2 (39.8, 44.6) 0.002 38.1 (35.4, 40.9) 47.7 (44.1, 51.2) <0.001
Age at diagnosis, median (range) 32.2 (13.8–70.1) 35.1 (13.2–70.0) n.s. 31.0 (14.5–65.8) 42.9 (20.7–71.5) 0.001
PSC duration, years, median (range) 0.2 (0–20.9) 2.9 (0.2–22.4) <0.001 0.6 (0.6–29.0) 3.2 (0–26.5) 0.039
IBD ever, n (%)* 41 (87.2) 98 (89.9) n.s. 70 (87.8) 32 (68.1) n.s.
Time of follow-up, yr, median (range) 11.8 (7.2–20.1) 1.4 (0–17.5) <0.001 2.8 (0.53–4.29) 0.4 (0–3.9) <0.001
Liver transplant, n (%) 0 85 (73.9) 0 33 (70.2)
Death as endpoint, n (%) 0 30 (26.1) 0 14 (29.8)
Mayo risk score, median (range)* 0.17 (2.24–2.91) 1.44 (1.39–5.26) <0.001 0.24 (2.37–3.20) 1.40 (0.95–4.13) <0.001
Laboratory data
ALP, U/L, median (range)* 413 (124–1883) 741 (70–3100) 0.022 204 (51–1459) 314 (82–892) <0.001
AST, U/L, median (range)* 57 (8–556) 108 (10–1012) 0.009 56 (16–1219) 100 (32–585) <0.001
ALT, U/L, median (range)* 110 (9–780) 108.5 (8–524) n.s. 74 (14–885) 99 (22–768) n.s.
Albumin, g/L, median (range)* 40 (22–50) 34 (15–46) <0.001 42 (28–50) 37 (23–46) <0.001
Total bilirubin, mmol/L, median (range)* 16 (5–227) 54 (5–567) <0.001 13 (3–175) 46 (5–532) <0.001
Creatinine, mmol/L, median (range)* 73.5 (51–98) 73 (41–216) n.s. 67 (39–91) 61 (37–111) n.s.
Platelets, 109/L, median (range)* 256 (10–756) 223 (35–879) 0.008 290 (65–903) 277 (22–759) n.s.
Differences between Tx-free survivors and patients who died or underwent liver transplantation were tested using Student’s t test or the Mann-Whitney U test for normally
and non normally distributed data, respectively.
Serum panel-1 and -2 represent independent PSC panels.
Tx, liver transplantation; n.s., not significant (p 0.05); IBD, inflammatory bowel disease; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
* Refers to a subpopulation of (A) n = 44–49, (B) n = 81–109, (C) n = 83–90, (D) n = 45–47.
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Explorative analysis of putative biomarkers by protein array analysis
The antibody array consisted of 144 well-characterized antibod-
ies targeting 63 proteins described to be involved in pathways
related to inflammation and fibrosis. Antibody array analysis
revealed 14 proteins that were significantly different between
PSC patients and controls (Table S3). The PSC patients were clas-
sified as having either early or advanced disease (ERC-based
Amsterdam score 0–2 or 3, respectively). Comparing early
and advanced PSC, 24 proteins showed significant differences
(Table S4). Subsequent analysis in an independent bile panel-2
(Table 1) replicated significant results for 13 proteins differing
between PSC and controls (Table S3). Eighteen of the 24 pro-
teins differing between mild and advanced disease in bile
panel-1 were also significantly different in bile panel-2
(Table S4).
Evaluation of the diagnostic utility of the novel bile biomarkers in
PSC
All of the 13 proteins that were consistently showing a significant
difference between PSC patients and controls were evaluated by
ROC-AUC analyses in bile panel-1 and bile panel-2 (Table 3). The
proteins performing best as single discriminators in the two pan-
els combined were IL-8, S100A12, LCN2, S100A8 (calprotectin)
and ITGB2. However, lasso analysis (optimizing subset selection
in order to enhance the prediction accuracy of the model it pro-
duces) identified ICAM1, MMP7, S100A4 and S100A12 as the
group of markers that collectively best distinguished PSC from
controls (Fig. 1A).Journal of Hepatology 2017Evaluation of the utility of the novel bile biomarkers in measuring
disease severity in PSC
In order to evaluate the ability of putative biomarkers to distin-
guish between mild and advanced disease, all proteins consis-
tently showing significant differences between mild and
advanced PSC in both bile panels, were evaluated by ROC-AUC
analyses in bile panel-1 and bile panel-2, respectively (Table 4).
The top three single targets best fit to distinguish mild from
advanced PSC were C5, calprotectin and TIMP1 (bile panel-1)
and S100A12, MPO, calprotectin and S100A7 (bile panel-2). Com-
bining ROC-AUC results, the targets best fit to distinguish
advanced from mild PSC were calprotectin (mean AUC 0.800),
S100A12 (mean AUC 0.787), TGFB1 (mean AUC 0.786) and
LCN2 (mean AUC 0.783). Lasso analysis identified calprotectin
alone as the protein best capturing the difference between mild
and advanced PSC (Fig. 1B).
Evaluation of the predictive value of the putative prognostic
biomarkers in peripheral blood
Serum analyses were performed in two independent cohorts
described in Table 2. In bile, seven proteins were significantly dif-
ferent between both PSC patients and controls and between PSC
patients with mild and advanced disease (IL-8, MMP9/LCN2 com-
plex, S100A12, TPH2, ITGB2 and calprotectin), and we considered
these as good candidates for further investigation.
In serum, IL-8 levels were significantly higher in PSC com-
pared to UC patients and healthy controls (median [range]: 39
[1–1891] pg/ml, 10.4 [1–1150] pg/ml and 3 [10–229] pg/ml,
respectively; p <0.001 for both comparisons; Fig. 2A). PSC
patients had higher levels of IL-8 compared to subgroups of UCvol. 66 j 1214–1222 1217
Table 3. Evaluation of putative biomarkers for PSC detection by ROC-AUC analyses.
Bile panel-1 Bile panel-2
Target Cut-off AUC 95% CI p value Sensitivity Specificity Cut-off AUC 95% CI p value Sensitivity Specificity
CD14 382 0.675 0.557, 0.779 0.02 94.6 40.0 1062 0.821 0.674, 0.921 <0.001 72.7 90.0
CLU 6606 0.734 0.619, 0.829 <0.001 69.1 75.0 3779 0.827 0.681, 0.925 <0.001 66.7 90.0
CXCL10 1365 0.686 0.569, 0.789 0.01 74.6 65.0 955 0.852 0.710, 0,941 <0.001 87.9 80.0
IL-8 12,115 0.734 0.619, 0.829 <0.001 72.7 70.0 5710 0.897 0.766, 0.969 <0.001 72.7 100.0
ITGB2 1665 0.692 0.575, 0.793 0.006 74.6 65.0 1907 0.924 0.801, 0.983 <0.001 84.9 100.0
LCN2 46,435 0.699 0.582, 0.800 0.007 70.9 70.0 40,193 0.945 0.830, 0.992 <0.001 81.8 100.0
LDHA 3461 0.660 0.541, 0.761 0.03 70.9 65.0 544 0.830 0.685, 0.927 <0.001 66.7 100.0
MMP7 25,117 0.717 0.601, 0.815 0.002 72.7 70.0 28,837 0.824 0.678, 0.923 <0.001 57.6 100.0
MMP9 4355 0.725 0.609, 0.821 0.004 89.1 60.0 6024 0.882 0.747, 0.960 <0.001 81.8 100.0
S100A4 22,260 0.730 0.615, 0.826 <0.001 67.3 85.0 18,437 0.879 0.743, 0.958 <0.001 72.7 100.0
S100A8 82,136 0.749 0.636, 0.842 <0.001 76.4 70.0 78,482 0.861 0.721, 0.947 <0.001 72.7 90.0
S100A12 13,512 0.764 0.651, 0.854 <0.001 85.5 65.0 32,916 0.876 0.739, 0.956 <0.001 72.7 100.0
TPH2 1040 0.679 0.561, 0.782 0.01 83.6 50.0 1901 0.891 0.758, 0.965 <0.001 78.8 100.0
The statistical analysis used is ROC-AUC analysis, as stated in the text.
ROC-AUC analysis was performed for each protein target showing significantly different levels in bile from primary sclerosing cholangitis (PSC) patients and disease
controls in both bile panel-1 and bile panel-2. The optimal cut-off was determined by Youden’s index.
AUC, area under the curve; CI, confidence interval; ROC-AUC, area under the curve of the receiver operating characteristics curve.
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Fig. 1. Identification of biomarker panels by lasso analysis. Lasso analysis
identified (A) ICAM1, MMP7, S100A4 and S100A12 as the group of markers that
collectively best distinguished primary sclerosing cholangitis (PSC) from controls
(AUC 0.85), and (B) S100A8 (S100A8/A9 complex; calprotectin) as the single
marker best distinguishing mild from advanced PSC, with no added value by
addition of other markers.
Research Articlepatients either active or in remission (median [range] 12 [1–
1038] pg/ml, p <0.001, and 8 [1–28] pg/ml, p <0.001, respec-
tively). IL-8 correlated with the ELF score and Mayo score
(serum panel-1: Spearman’s rho 0.68 and 0.59, respectively;
p <0.001 for both; serum panel-2: Spearman’s rho 0.64 and
0.46, respectively; p <0.001 for both). Exploration of serum
panel-1 by Kaplan-Meier plot analysis showed a significant
inverse association between IL-8 levels and transplant-free sur-
vival for PSC patients (log-rank test: Chi-square 31.2, p <0.001;
Fig. 2B). This was replicated in serum panel-2 (Fig. 2C).
PSC patients had lower serum levels of the MMP9/LCN2 com-
plex compared to either UC or healthy controls (median [range]
3.9 [0.2–150.0], 21.6 [0.9–130.0] and 15.3 [1.4–65.6], respec-
tively; p <0.001 for both comparisons). Likewise, S100A12 levels
were lower in PSC compared to either UC or healthy controls
(median [range] 7.4 [1.0–30.0], 8.6 [1.0–28.2] and 9.2 [1.0–
16.9], respectively; p = 0.001 and p <0.001, respectively). No asso-
ciations with survival were found for S100A12, the MMP9-LCN2
complex or TPH2 (log-rank test: Chi-square 0.73 [p = 0.70], 3.60
[p = 0.17] and 1.63 [p = 0.20], respectively; Fig. S2A and B).1218 Journal of Hepatology 2017Plasma (only available from panel-2) calprotectin (S100A8/
A9) levels were not significantly different between PSC patients
and controls (median [range] 414.6 [89.2–2501.0] and 424.7
[153.9–1557.2], respectively; p = 0.62; Fig. S2C). No significant
differences in survival were found for tertiles of calprotectin
using log-rank test (p = 0.32, Fig. S2D), although further explo-
ration of the data identified a weak association with poorer prog-
nosis in the upper quartile when comparing with the other
patients (p = 0.03; Fig. S2E and F).
Prognostic modeling of novel and previously reported biomarkers in
PSC
Results from univariate Cox proportional hazards regression
analysis including all patients with complete data in the deriva-
tion and the validation panels, respectively, are listed in Table 5.
Age, age at diagnosis, bilirubin, albumin, AST, INR, the Mayo risk
score, ELF score and IL-8 showed a significant (p <0.05) associa-
tion with transplant-free survival consistently in both panels.
We have previously reported that the ELF score and Mayo risk
score are both independently associated with transplant-free sur-
vival [7]. Owing to collinearity (rho >0.5), we assessed IL-8 in a
Cox model separate from ELF and Mayo score in the multivariable
analyses. Other variables showing collinearity with IL-8 were also
excluded.
In serum panel-1, multivariable Cox regression analysis
including IL-8 and sex, age at diagnosis, PSC duration, serum pla-
telets and albumin, yielded a final model including IL-8 (HR 1.18
95% CI [1.01, 1.37], p = 0.04), age at diagnosis (HR 1.02, 95% CI
[1.00, 1.04], p = 0.02), PSC duration (HR 1.09, 95% CI [1.05,
1.14], p <0.001) and albumin (HR 0.90, 95% CI [0.87, 0.93],
p <0.001); whereas in serum panel-2, the identical analysis
yielded a final model including IL-8 (HR 1.50, 95% CI [1.18,
1.91], p = 0.001), age at diagnosis (HR 1.05, 95% CI [1.02, 1.07],
p <0.001), platelets (HR 0.59, 95% CI [0.35, 0.99], p = 0.04) and
albumin (HR 0.92, 95% CI [0.87, 0.97], p = 0.002) (Table 6). When
patients in serum panel-1 were divided by the median Mayo
score, repeating the analysis showed a final model including
IL-8 in the low-Mayo score group but not in the high-Mayo score
group (Table S5). In a multivariable analysis adding serumvol. 66 j 1214–1222
Table 4. Evaluation of the usefulness of putative biomarkers in bile to distinguish mild and advanced PSC.
Bile panel-1 Bile panel-2
Target Cut-off AUC 95% CI p value Sensitivity Specificity Cut-off AUC 95% CI p value Sensitivity Specificity
C5 1358 0.745 0.606, 0.855 0.002 87.9 60.0 3188 0.713 0.526, 0.858 0.021 57.9 84.6
CAT 31,887 0.685 0.543, 0.806 0.023 75.8 65.0 58,681 0.810 0.632, 0.926 <0.001 63.2 100.0
CD177 1898 0.717 0.576, 0.832 0.004 72.7 75.0 5364 0.717 0.530, 0.861 0.021 57.9 100.0
CHI3L1 1078 0.675 0.532, 0.797 0.022 63.6 80.0 2031 0.729 0.543, 0.870 0.013 42.1 100.0
IL-1B 371 0.680 0.538, 0.802 0.026 72.7 65.0 522 0.783 0.603, 0.909 <0.001 57.9 100.0
IL-6 359 0.701 0.559, 0.819 0.008 69.7 70.0 1484 0.688 0.501, 0.839 0.048 42.1 92.3
IL-8 49,225 0.702 0.560, 0.819 0.008 57.6 85.0 23,956 0.854 0.685, 0.953 <0.001 80.0 84.6
ITGB2 5049 0.680 0.537, 0.801 0.020 60.6 80.0 5056 0.842 0.670, 0.946 <0.001 73.7 92.3
LCN2 74,071 0.720 0.579, 0.834 0.003 72.7 75.0 49,516 0.846 0.675, 0.949 <0.001 89.5 69.2
MMP8 22,819 0.670 0.527, 0.793 0.028 54.6 85.0 19,839 0.830 0.656, 0.939 <0.001 63.2 92.3
MMP9 114,780 0.699 0.558, 0.818 0.007 48.5 95.0 29,733 0.794 0.614, 0.916 <0.001 63.2 92.3
MPO 37,498 0.680 0.538, 0.802 0.025 66.7 70.0 17,003 0.866 0.699, 0.960 <0.001 89.5 76.9
S100A7 2259 0.692 0.551, 0.812 0.011 54.6 90.0 2109 0.858 0.690, 0.956 <0.001 79.0 84.6
S100A8 261,601 0.742 0.604, 0.853 <0.001 66.7 80.0 206,305 0.858 0.690, 0.956 <0.001 79.0 84.6
S100A12 408,500 0.682 0.540, 0.803 0.016 51.5 85.0 111,312 0.891 0.730, 0.973 <0.001 79.0 92.3
TGFB1 3943 0.717 0.576, 0.832 0.004 66.7 75.0 4917 0.854 0.685, 0.953 <0.001 63.2 100.0
TIMP1 221 0.728 0.588, 0.841 0.001 63.6 85.0 221 0.769 0.587, 0.899 0.002 63.2 92.3
TPH2 3181 0.683 0.541, 0.804 0.016 45.5 90.0 5118 0.733 0.547, 0.873 0.009 47.4 100.0
The statistical analysis used is ROC-AUC analysis, as stated in the text.
ROC-AUC analysis was performed for each protein target showing significantly different levels in bile from primary sclerosing cholangitis (PSC) patients with mild and
advanced disease as assessed by the Amsterdam score in both bile panel-1 (N = 53) and bile panel-2 (N = 32). The optimal cut-off was determined by Youden’s index.
AUC, area under the curve; CI, confidence interval; ROC-AUC, area under curve of the receiver operating characteristic.
JOURNAL OF HEPATOLOGYbilirubin to the analysis, IL-8 was still an independent predictor
of transplant-free survival in serum panel-2; whereas in serum
panel-1, IL-8 was not part of the final model (Table S6). The Mayo
score and ELF score were assessed in separate analyses excluding
IL-8, and the final models included independent associations of
Mayo score and ELF score with outcome as previously reported
(data not shown) [7]. Application of an alternative endpoint
defined as liver failure related transplantation or death, con-
firmed an independent association of IL-8 with prognosis
(Fig. S3 and Table S7).
Given the possible association between plasma calprotectin
and progression only investigated in panel-2, we also performed
univariable Cox regression with Ln calprotectin, which was sig-
nificant (HR 1.60 [1.04, 2.47], p = 0.03). In multivariable models,
plasma calprotectin was an independent predictor in all models
(Table S8), with a final model including Ln calprotectin (HR
1.65 [1.07, 2.54], p = 0.03), Mayo score (HR 1.54 [1.15, 2.08],
p = 0.004) and ELF test (HR 1.41 [1.09, 1.83], p = 0.008).Discussion
In this exploratory study, through the use of advanced antibody
array technology we identified in ductal bile a number of proteins
related to inflammation and fibrosis that were associated with
disease activity or severity in a large number of PSC patients.
We considered as true findings only results that were validated
by replication in an independent panel. Out of the eighteen pro-
teins differing between mild and advanced PSC, lasso analysis
showed that calprotectin alone best captured the difference
between mild and severe disease in PSC. Serum analyses identi-
fied IL-8 as the best predictor of transplant-free survival in PSC
out of the identified inflammatory markers.
In the present study we found a widely different proteomic
profile between patients with and without PSC, and between
PSC patients with early and advanced disease. In contrast to pre-Journal of Hepatology 2017vious reports focusing on the predictive value of markers of fibro-
sis like ELF in PSC, the results of the present study highlight the
importance of inflammation. From the lists of suggested diagnos-
tic or prognostic markers, seven proteins were associated both
with PSC as such, and with PSC severity, namely IL-8, ITGB2,
LCN2, MMP9, calprotectin, S100A12 and TPH2. Interestingly, all
of these are markers of inflammation, except for TPH2 which is
a marker of proliferation [17].
IL-8 attracts and activates neutrophils, leading to the release
of a wide variety of substances including S100A8/A9, S100A12
and MMP9, also highlighted by the present data. Previous reports
have also demonstrated elevated serum IL-8 levels in various
chronic liver diseases, with increased levels associated with
advanced stages of fibrosis and cirrhosis. Interestingly, higher
levels were found in cholestatic liver disease compared to other
etiologies, and in PSC patients compared to healthy controls
[18,19]. IL-8 has also been implicated in biliary atresia, another
cholestatic disease [20]. Moreover, an elevated expression of IL-
8 was observed in cholangiocytes from PSC livers compared to
cholangiocytes from the livers of patients with PBC, hepatitis C
virus and normal liver [21]. In the same study, exposure to LPS
induced a state of hypersecretion of IL-8 by the biliary epithelial
cells, suggesting a possible link to IBD and the leaky gut hypoth-
esis. Overall, the very high concentrations of IL-8 both in bile and
serum and the link to disease severity as well as prognosis sug-
gest that it has an important role in PSC, and that the cellular
source, at least in part, may be the biliary epithelium. Of note,
cholangiocyte senescence with transition of cholangiocytes to a
pathological state involving, amongst other things, hypersecre-
tion of IL-8, has been suggested as a putative contributing factor
in PSC pathogenesis [21]. Studies to further detail the roles of IL-8
in cholangiocyte biology and its relevance in biliary inflammation
appear warranted based on the available data.
Biliary calprotectin was both associated with PSC per se and
PSC severity, as evaluated by the Amsterdam score. This is in line
with previous reports proposing calprotectin as a bile proteinvol. 66 j 1214–1222 1219
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Fig. 2. Prediction of transplant-free survival by serum biomarkers (IL-8). (A)
Elevated serum IL-8 levels in PSC (n = 305) compared to UC (n = 98) or healthy
controls (n = 100). (B and C) Kaplan-Meier curves of time to transplantation (Tx)
or death for PSC patients stratified into tertiles of IL-8 for serum panel-1 (B) and
serum panel-2 (C), respectively, illustrating that in patients in the lower tertile of
IL-8 (solid line), survival was significantly longer compared to the intermediate
and high IL-8 tertiles (dashed line and dotted line, respectively). PSC, primary
sclerosing cholangitis; UC, ulcerative colitis.
Research Articlemarker for disease activity in PSC [22–24]. Calprotectin was pre-
viously shown to correlate with the Mayo risk score in PSC
patients regardless of the presence or absence of IBD. Calpro-1220 Journal of Hepatology 2017tectin is involved in the promotion of inflammatory responses
in several autoimmune diseases as well as in inflammation-
associated cancer, acting in part via Toll-like receptor 4, which
has also been implicated in PSC [22]. In IBD, calprotectin is a
well-established fecal marker of colonic inflammation and a com-
mercially available test is widely used in the clinical follow-up
[25]. In analogy to this, it appears an intriguing opportunity
whether assays for calprotectin could be modified for the assess-
ment of calprotectin levels in bile sampled at ERC to provide
severity assessments. The observed association between plasma
calprotectin and disease progression in one study panel is
promising but needs validation in independent cohorts.
We have previously demonstrated that a biomarker panel for
fibrosis, the ELF score, based on three direct components of liver
fibrogenesis, is well suited to stratify PSC patients into groups of
differing prognosis [3]. In the present study, we show that the
Mayo risk score and ELF score are likely to be stronger predictors
of clinical outcome compared to IL-8. However, IL-8 was associ-
ated with transplant-free survival in multivariable analyses in
two independent PSC cohorts, indicating an important influence
on PSC progression. Our findings underline the implication of
IL-8, as a marker of inflammation, in the pathogenesis of PSC.
Interestingly, novel data confirming increased levels of IL-8 in
the bile of PSC patients compared to controls indicate that IL-8
stimulates proliferation and fibrogenic gene expression in pri-
mary human cholangiocytes, linking the primarily inflammatory
marker IL-8 also to fibrosis development [26]. Taken together, the
inflammatory pathways represented by IL-8 may thus harbor
potential treatment targets for PSC, and mechanistic studies to
elaborate the relationship between IL-8 production and fibrosis
development are warranted.
The large number of putative biomarkers explored using
extensively validated antibodies and the validation of results in
independent patient panels represent strengths of the present
study. Limitations include its retrospective design. In future,
improved proteomic techniques might allow a more comprehen-
sive unbiased analysis in bile. Any bias of ERC indication (diag-
nostic vs. intervention) was not evaluated due to uncertainty of
available retrospective data and should be assessed in subse-
quent prospective cohorts. The bile panel disease control groups
included non-cholestatic diseases perhaps more relevant for
investigation of pathogenetic pathways than assessment of diag-
nostic utility; however, ERC-bile samples were scarce, complicat-
ing tailoring of optimal control panels. All patients in the present
series were included at a tertiary referral center and may repre-
sent more severely affected subgroups. The long follow-up
allowed us to use all-cause death and liver transplantation as
combined endpoints, however, we acknowledge that lead-time
bias may influence the accuracy of such measures.
Through exploration of a wide range of putative biomarkers in
the bile of PSC patients in two independent patient panels, we
have identified multiple proteins related to inflammation distin-
guishing mild from advanced disease, including IL-8 and calpro-
tectin. Serum analyses in two independent PSC patient panels
demonstrated that serum IL-8 was predictive of liver transplanta-
tion free survival, suggesting a contribution of IL-8 associated
inflammatory mechanisms to PSC pathogenesis. Subanalyses in
groups defined by Mayo score seemed to support a role of IL-8
particularly in early PSC. While markers of disease stage (Mayo
risk score) and fibrosis (ELF score) were stronger predictors of
survival than IL8, our data strongly suggest that inflammatoryvol. 66 j 1214–1222
Table 5. Univariate Cox regression analyses of factors affecting the transplant-free survival in PSC patients in serum panel-1 and -2, respectively.
Serum panel-1 Serum panel-2
HR 95% CI p value N HR 95% CI p value N
Age 1.03 1.02, 1.04 <0.001 167 1.05 1.02, 1.07 <0.001 138
Sex 1.10 0.71, 1.70 0.683 167 0.62 0.33, 1.19 0.151 138
Age at diagnosis 1.02 1.01, 1.03 0.005 167 1.04 1.02, 1.06 <0.001 138
PSC duration 1.07 1.04, 1.10 <0.001 167 1.03 0.99, 1.07 0.211 138
IBD status ever 0.70 0.35, 1.39 0.308 156 1.57 0.85, 2.89 0.152 137
Bilirubin 1.80 1.52, 2.12 <0.001 153 2.24 1.73, 2.88 <0.001 130
Albumin 0.89 0.86, 0.91 <0.001 141 0.86 0.82, 0.91 <0.001 129
ALP 1.23 0.93, 1.63 0.141 139 2.35 1.57, 3.53 <0.001 130
AST 1.33 1.05, 1.68 0.017 153 1.73 1.28, 2.35 <0.001 130
ALT 0.90 0.74, 1.10 0.307 154 1.17 0.84, 1.63 0.361 130
Platelet count 0.68 0.52, 0.89 0.005 125 0.66 0.43, 1.01 0.053 129
APRI score (AST/TRC) 0.99 0.94, 1.04 0.690 121 1.38 1.17, 1.63 <0.001 129
INR 3.43 1.92, 6.12 <0.001 95 17.98 5.01, 64.52 <0.001 113
Variceal bleeding 0.54 0.26, 1.11 0.093 147 2.59 0.80, 8.35 0.112 138
Mayo score 1.75 1.52, 2.02 <0.001 125 2.06 1.67, 2.54 <0.001 129
ELF score 2.27 1.89, 2.73 <0.001 167 2.29 1.78, 2.95 <0.001 138
MMP9-LCN2 0.99 0.95, 1.03 0.541 167 0.99 0.98, 1.01 0.482 138
S100A12 1.02 0.98, 1.07 0.339 167 0.94 0.86, 1.02 0.148 138
TPH2 n.a. n.a. n.a. n.a. 1.00 1.00, 1.00 0.102 138
S100A8/A9 n.a. n.a. n.a. n.a. 1.60 1.04, 2.47 0.033 138
IL-8 1.00 1.00, 1.00 0.003 167 1.00 1.00, 1.01 0.001 138
The table shows the results of univariate Cox regression analyses of relevant clinical and laboratory variables.
Bilirubin, ALP, AST, ALT, and platelet count were transformed by the natural logarithm prior to regression analyses due to a right-skewed distribution.
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; ELF, enhanced liver fibrosis; HR, hazard ratio; INR,
international normalized ratio; IBD, inflammatory bowel disease; IL8, interleukin-8; MMP9-LCN2, the complex of matrix metalloproteinase-9 and lipocalin-2; PSC, primary
sclerosing cholangitis; S100A8/A9, calprotectin; S100A12, S100 calcium-binding protein A12 (calgranulin-C); TPH2, tryptophan hydroxylase 2.
Table 6. Multiple Cox proportional hazards model.
Serum panel-1 Serum panel-2
HR 95% CI p value HR 95% CI p value
Age at diagnosis 1.02 1.00, 1.04 0.02 1.05 1.02, 1.07 <0.001
PSC duration 1.09 1.05, 1.14 <0.001
Thrombocytes 0.59 0.35, 0.99 0.04
Albumin 0.90 0.87, 0.93 <0.001 0.92 0.87, 0.97 0.002
IL-8 1.18 1.01, 1.37 0.04 1.50 1.18, 1.91 0.001
The table shows the results of multivariable Cox regression analysis.
The analysis was performed in serum panel-1 (n = 116) and in serum panel-2 (n = 128), respectively, entering the following variables: Sex, age at diagnosis, PSC duration,
serum albumin, serum platelets and serum IL-8. The natural logarithm was used for platelets and IL-8 because of right-skewed distribution. Sex and all variables showing
significant association in the univariate analyses were included, except for variables showing collinearity with IL-8 (r >0.5) in any of the panels (ELF score, Mayo score,
serum bilirubin and serum AST) which were assessed in separate analyses, see Table S4). Age and age at diagnosis were strongly correlated, and therefore only age at
diagnosis was included (similar results were achieved if age was substituted for age at diagnosis).
JOURNAL OF HEPATOLOGYmarkers should be included alongside fibrosis markers in the fur-
ther search for parameters providing a comprehensive descrip-
tion of PSC severity and progression.Financial support
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